Vanda Pharmaceuticals Inc. develops and sells clinical-stage products for various central nervous system disorders. The main product marketed by Vanda Pharmaceuticals is Fanapt, which is drug used for the acute treatment of schizophrenia in adults. The company is currently developing another product called Tasimelteon, which is in the orphan designation status for the treatment of non-24 hour sleep/wake disorder in blind individuals without light perception. It is also developing Tasimelteon in Phase II trials for the treatment of depression. The company was incorporated in 2002.
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) continues the free fall started at the end of last month, after analyst Madison Williams announced a severe target price cut for the medical stock from $16 to $7 for a share.read more
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) continues the free fall started at the end of last month, after analyst Madison Williams announced a severe target price cut for the medical stock from $16 to $7 for a share.read more
